Table 2.
Examples of disease-specific treatment satisfaction patient-reported outcome (PRO) instruments
| Name | Objective | Population | Recall period | Items | Domains | Psychometric properties* |
|---|---|---|---|---|---|---|
|
The Diabetes Treatment Satisfaction Questionnaire (DTSQ): |
To measure satisfaction with diabetes treatment regimens in people with diabetes and changes in satisfaction with treatment | Adult |
DTSQs: over the past few weeks DTSQc: 6 months ago (before you changed to the medication you are using now) |
8 |
Satisfaction with treatment (6 items) Perceived hyperglycaemia (1 item) Perceived hypoglycaemia (1 item) |
Reliability: Internal consistency reliability: Cronbach's alpha coefficient Insulin-dependent diabetes; n = 128 0.76 (For the Satisfaction with treatment scale) Type 2 diabetes; n = 181 Cronbach's alpha coefficient 0.79 Validity: Clinical validity Type 2 diabetes; n = 181 According to the percent of ideal body weight, HbA1 levels, subjective estimates of diabetic control Greater treatment satisfaction was associated with being less overweight (r = −0.19; p < 0.01); better blood glucose control as indicated by lower HbA1 levels (r = −0.28; p < 0.001); optimistic patient estimates of recent diabetic control (r = −0.56; p < 0.001) |
| Cancer Therapy Satisfaction Questionnaire (CTSQ) [46, 47] | To measure satisfaction with and preference for chemotherapy treatment, and for biological therapy in either pill or intravenous administration form | Adult | In the last 4 weeks | 16 |
Expectations of Therapy (ET): 5 items Feelings about side effects (FSE): 4 items Satisfaction with therapy (SWT): 7 items |
Reliability: Internal consistency reliability; Cronbach's alpha coefficients: Oncology patients; n = 361 Expectations of therapy: 0.87; Feelings about side effects: 0.77; Satisfaction with therapy: 0.82; Convenience: 0.60 Test-retest reliability (reproducibility): Intraclass correlation coefficient: Oncology patients; n = 53 Expectations of therapy: 0.68; Feelings about side effects: 0.82; Satisfaction with therapy: 0.732 Validity: Clinical validity Oncology patients; n = 361. Cancer stage: ANOVA. ET domain (p = 0.005). Effect size 0.67 Stages I and IV. ECOG performance status. ET domain. Grades 0, 1, and 2 (p = 0.0007). Effect size 0.46 for Grades 0 vs 1. Correlation coefficient: one-way ANOVA Ability to detect change: Minimal Important Difference (MID): ET: 9.59 (0.5 SD of baseline scores); FSE 11.00 (0.5 SD of baseline scores); SWT: 6.88 (0.5 SD of baseline scores) |
| The Erectile Dysfunction Index of Treatment Satisfaction (EDITS) [48] | To assess satisfaction with medical treatments for erectile dysfunction | Adult | In the past 4 weeks |
Patient: 11 Partner: 5 |
Treatment satisfaction |
Reliability: Internal consistency reliability Couples with men having erectile dysfunction: n = 28 couples for the Patient EDITS version, and n = 29 couples for the Partner EDITS version Cronbach's alpha coefficient: 0.90 for the patients; 0.76 for the partners Test-retest reliability (reproducibility) Couples with men having erectile dysfunction: n = 28 couples for the Patient EDITS version, and n = 29 couples for the Partner EDITS version Spearman rank-order correlations: 0.98 for the Patient EDITS and 0.83 for the Partner EDITS |
| Pain Treatment Satisfaction Scale (PTSS) [48] | To measure patient satisfaction for patients receiving treatment for either acute or chronic pain | Adult | Present time, last week or last 24 hours | 39 + 22 not scored |
Information (5 items) Medical care (8 items) Impact of current pain medication (8 items) Satisfaction with pain medication (2 subscales: medication characteristics [3 items] + efficacy [3 items]) Side effects (12 items) + general health items (6 items) and stand-alone questions (not scored—providing complementary information) |
Reliability: Internal consistency reliability: Cronbach's alpha coefficient: Patients with acute pain (n = 111) and chronic pain (n = 89), n = 208 Satisfaction with current pain medication: 0.90; Efficacy subscale: 0.90; Medication characteristics subscale: 0.85; Side effects of medication: 0.83; Impact of current pain medication: 0.92; Medical care: 0.86; Information about pain and its treatment: 0.89 Test-retest reliability (reproducibility) a) Intraclass Correlation Coefficient (ICC) Satisfaction with current pain medication: 0.974; Efficacy subscale: 0.76; Medication characteristics subscale: 0.55; Side effects of medication: 0.67; Impact of current pain medication: 0.68; Medical care: 0.81; Information about pain and its treatment: 0.76 b) Wilcoxon signed rank test Patients with chronic pain; n = 87. All dimensions except information, mean scores were not significantly different between baseline and week 2; p > 0.05 Validity: Clinical validity Patients with acute pain (n = 111) and chronic pain (n = 89), n = 208. Spearman's correlation coefficient Satisfaction with current pain medication: −0.48; Efficacy subscale: −0.53; Medication characteristics subscale: −0.35; Side effects of medication: −0.17; Impact of current pain medication: −0.25; Medical care: −0.32; Information about pain and its treatment: −0.29 Known-groups validity Patients with acute pain (n = 111) and chronic pain (n = 89), n = 208 Pain severity in the last week: Scores were significantly lower (except medical care) in patients with severe pain. Pain severity after treatment: Scores were significantly lower in all scales (p < 0.05) in patients with severe pain. Pain severity in the last week, in the last 24 h and right now: PTSS scores were systematically lower in patients reporting more severe pain. The differences were significant for medication characteristics and side effects Ability to detect change: Patients with acute pain: n = 104. Mean ABLE change scores differed significantly for the improved group of patients based on the change in pain (p < 0.05), Wilcoxon signed rank test |
*Psychometric properties data sourced from ePROVIDE’s PROQOLID Database [43]